NeuroSense Therapeutics Ltd.
NRSN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NRSN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NRSN
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, with its lead candidate PrimeC for ALS currently in clinical trials.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Tracking 2 clinical trials for NeuroSense Therapeutics Ltd..
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, with its lead candidate PrimeC for ALS currently in clinical trials.
- Lead product candidate PrimeC is in clinical development for ALS, with an IND cleared by the FDA in March 2022 [sec · filed 2026-03-31].
- Cash and cash equivalents were $0.2 million as of December 31, 2025 [sec · filed 2026-03-31].
- Net loss was $11.1 million for the year ended December 31, 2025 [sec · filed 2026-03-31].
- Shareholders' equity was $2.6 million as of December 31, 2025 [latest reported financials (authoritative, structured)].
- The company has incurred significant losses and negative cash flows since inception and expects to continue doing so [sec · filed 2026-03-31].
What works
- PrimeC has received FDA IND clearance, allowing clinical development to proceed in the U.S. [sec · filed 2026-03-31].
- The company is actively advancing PrimeC through clinical trials, targeting a large unmet medical need in ALS [sec · filed 2026-03-31].
What to weigh
- Cash of $0.2 million as of December 31, 2025 is insufficient to fund operations for 12 months, raising substantial doubt about going concern [sec · filed 2026-03-31].
- The company has a history of significant losses and negative cash flows, with a net loss of $11.1 million in 2025 [sec · filed 2026-03-31].
- All product candidates are in preclinical or clinical stages and have not received marketing approval from any regulatory agency [sec · filed 2026-03-31].
- Raising additional capital may cause dilution or require relinquishing rights to technologies or product candidates [sec · filed 2026-03-31].
From the filings
Quoted directly from source documents.
Cash position is critically low and raises going concern doubts.
“As of December 31, 2025, we had cash and cash equivalents of $0.2 million.”
SEC filings · March 31, 2026
The company has incurred significant net losses.
“net losses of $11.1 million and $10.2 million for the years ended December 31, 2025 and 2024, respectively.”
SEC filings · March 31, 2026
PrimeC is the lead candidate and has FDA IND clearance.
“the FDA's timely acceptance of our IND filing for our product candidates other than PrimeC for which we filed an IND and received clearance in March of 2022;”
SEC filings · March 31, 2026
The company's ability to continue as a going concern is in doubt.
“our financial status creates a doubt whether we will continue as a going concern.”
SEC filings · March 31, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash of $0.2M as of Dec 31, 2025 is insufficient for 12 months of operations [sec · filed 2026-03-31].
- No approved products — All candidates are in preclinical/clinical stages; none have received marketing approval [sec · filed 2026-03-31].
- Dilution from fundraising — Raising capital may cause dilution or require relinquishing rights [sec · filed 2026-03-31].
- Nasdaq listing risk — Ability to maintain listing on Nasdaq is uncertain [sec · filed 2026-03-31].
What to watch
- Progress and timing of PrimeC clinical trials, as they are central to the company's future [sec · filed 2026-03-31].
- Ability to raise additional capital through equity sales or other financing [sec · filed 2026-03-31].
- Any regulatory milestones or updates regarding PrimeC or other candidates [sec · filed 2026-03-31].
- Changes in cash position and operating results in future filings [sec · filed 2026-03-31].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run NeuroSense Therapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NeuroSense Therapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.1 months
OCF -$8M · Net income -$11M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$131K
| Holder | Shares | Value |
|---|---|---|
| two sigma investments, lp | 44,445 | $34K |
| meitav investment house ltd | 40,000 | $30K |
| jane street group, llc | 28,670 | $22K |
| commonwealth equity services, llc | 22,775 | $17K |
| pnc financial services group, inc. | 21,150 | $16K |
| geode capital management, llc | 15,870 | $12K |
| jones financial companies lllp | 1,000 | $731 |
| sbi securities co., ltd. | 265 | $200 |
Short Interest
as of Apr 30, 2026- % of float
- 2.4%
- Days to cover
- 3.5
- Shares short
- 653,788
- Daily short volume (Aug 14, 2026)
- 45.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NRSN short interestFrequently asked questions
What is the AI investment thesis for NeuroSense Therapeutics Ltd.?
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, with its lead candidate PrimeC for ALS currently in clinical trials.
Who is the CEO of NeuroSense Therapeutics Ltd.?
Mr. Alon Ben-Noon is the chief executive officer of NeuroSense Therapeutics Ltd. (NRSN).
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. (NRSN) is headquartered in Herzliya, Israel.
What therapeutic areas does NeuroSense Therapeutics Ltd. focus on?
NeuroSense Therapeutics Ltd. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.